Kondo Motonari, Wagers Amy J, Manz Markus G, Prohaska Susan S, Scherer David C, Beilhack Georg F, Shizuru Judith A, Weissman Irving L
Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Annu Rev Immunol. 2003;21:759-806. doi: 10.1146/annurev.immunol.21.120601.141007. Epub 2002 Dec 17.
Stem cell biology is scientifically, clinically, and politically a current topic. The hematopoietic stem cell, the common ancestor of all types of blood cells, is one of the best-characterized stem cells in the body and the only stem cell that is clinically applied in the treatment of diseases such as breast cancer, leukemias, and congenital immunodeficiencies. Multicolor cell sorting enables the purification not only of hematopoietic stem cells, but also of their downstream progenitors such as common lymphoid progenitors and common myeloid progenitors. Recent genetic approaches including gene chip technology have been used to elucidate the gene expression profile of hematopoietic stem cells and other progenitors. Although the mechanisms that control self-renewal and lineage commitment of hematopoietic stem cells are still ambiguous, recent rapid advances in understanding the biological nature of hematopoietic stem and progenitor cells have broadened the potential application of these cells in the treatment of diseases.
干细胞生物学在科学、临床和政治方面都是当前的热门话题。造血干细胞是所有类型血细胞的共同祖先,是体内特征最明确的干细胞之一,也是临床上唯一用于治疗乳腺癌、白血病和先天性免疫缺陷等疾病的干细胞。多色细胞分选不仅能够纯化造血干细胞,还能纯化其下游祖细胞,如常见淋巴祖细胞和常见髓系祖细胞。包括基因芯片技术在内的近期遗传学方法已被用于阐明造血干细胞和其他祖细胞的基因表达谱。尽管控制造血干细胞自我更新和谱系定向的机制仍不明确,但最近在理解造血干细胞和祖细胞生物学特性方面的快速进展拓宽了这些细胞在疾病治疗中的潜在应用。